



89bio to Present Additional Pegzofermin Data at EASL International Liver Congress™ 2022

June 21, 2022

SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegzofermin data in non-alcoholic steatohepatitis (NASH) will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, to be held in London, UK on June 22-26, 2022.

Presentation details are as follows:

Abstract Title: Pegzofermin Led to Improved Liver Histology, Liver-related Non-invasive Tests and Metabolic Profile, With Favorable Safety and Tolerability, in an Open-label Cohort of a Phase 1b/2a Study in Subjects With Non-alcoholic Steatohepatitis

Abstract Number: 3535

Format: Poster presentation (#SAT-139)

Presenting Author: Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego

Presentation Date and Time: Saturday, June 25th 9:00 – 18:30 BST

Abstract Title: Pegzofermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH)

Abstract Number: 3654

Format: Poster presentation (#SAT-143)

Presenting Author: Naim Alkhouri, MD, Chief of Transplant Hepatology and Director of the Fatty Liver Program, Arizona Liver Health (ALH)

Presentation Date and Time: Saturday, June 25th 9:00 – 18:30 BST

Abstract Title: Pharmacokinetics (PK) and Pharmacodynamics (PD) of BIO89-100, a Novel GlycoPEGylated FGF21, in Nonalcoholic Steatohepatitis (NASH) Patients with Compensated Cirrhosis

Abstract Number: 1520

Format: Poster presentation (#SAT-131)

Presenting Author: Naim Alkhouri, MD, Chief of Transplant Hepatology and Director of the Fatty Liver Program, Arizona Liver Health (ALH)

Presentation Date and Time: Saturday, June 25th 9:00 – 18:30 BST

About 89bio

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegzofermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegzofermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on [LinkedIn](#).

Investor Contact:

Ryan Martins

Chief Financial Officer

investors@89bio.com



Source: 89bio, Inc.